Fiduciary Alliance LLC Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fiduciary Alliance LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 8,322 shares of the biopharmaceutical company’s stock, valued at approximately $398,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HALO. Congress Asset Management Co. grew its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares in the last quarter. Boston Trust Walden Corp boosted its position in Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after buying an additional 239,321 shares during the period. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Finally, South Street Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on HALO shares. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright increased their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Get Our Latest Analysis on HALO

Halozyme Therapeutics Trading Down 0.6 %

NASDAQ HALO opened at $53.83 on Wednesday. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a 50 day moving average price of $49.95 and a 200 day moving average price of $54.06. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.85 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.